Results 41 to 50 of about 24,744 (229)

Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor Alpha and Gamma Agonists on Myocardial Damage: Molecular Mechanisms and Clinical Evidence—A Narrative Review

Cells
Cardiovascular diseases remain the leading cause of death in the world, and that is why finding an effective and multi-functional treatment alternative to combat these diseases has become more important.
María Esther Rubio-Ruíz, Juan Carlos Plata-Corona, Elizabeth Soria-Castro, Julieta Anabell Díaz-Juárez, María Sánchez-Aguilar   +4 more
doaj   +1 more source

Correlations Among Glycemia and Glucose Variability, Thyroid Hormones, and Albuminuria in Patients With Type 2 Diabetes Mellitus

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Hyperglycemia, glucose fluctuations, and thyroid dysfunction contribute to the progression of diabetic nephropathy. This study aimed to investigate the associations of glycemia, glucose variability, and thyroid hormones with albuminuria in patients with type 2 diabetes mellitus (T2DM). In total, 451 T2DM patients were included.
Na Luo, Shang‐Yong Feng, Hui Chen, Dun‐Min She, Yan Liu, Ying Li, Cai‐Feng Yan, Zhen‐Wen Zhang, Jing Chen, Xiao‐Li Cai, Gao‐Yu Zhao, Hui Yu, Yan Wang   +12 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Thiazolidinediones and fluid retention [PDF]

Kidney International, 2007
CASE PRESENTATION A 67-year-old Caucasian woman was admitted to our hospital with progressive shortness of breath and swelling of all four extremities. Her past medical history included type 2 diabetes and hypertension of approximately 20 and 10 years of duration, respectively, hypothyroidism, morbid obesity, paroxysmal atrial fibrillation, and ...
Kiryluk, K., Isom, R.
openaire   +2 more sources

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

The Journal of Dermatology, EarlyView.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes

Frontiers in Pharmacology
The therapeutic targeting of peroxisome proliferator-activated receptor gamma (PPARγ) for type 2 diabetes (T2D) remains a double-edged sword: while thiazolidinediones are efficacious, their severe side effects necessitate the discovery of safer ...
Kalpana Panati, Parasuraman Aiya Subramani, Venkata Ramireddy Narala   +2 more
doaj   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Safety and Effectiveness of Rosiglitazone in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease

Journal of the Formosan Medical Association, 2006
Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease ranging in severity from steatosis to cirrhosis. Type 2 diabetes mellitus is a cause of primary NAFLD.
Chao-Hung Wang, Ching-Hsiang Leung, Sung-Chen Liu, Cheng-Ho Chung   +3 more
doaj   +1 more source

Transcriptomic and metabolomic analyses reveal that lobeglitazone ameliorates hepatic steatosis in rats concurrent with regulation of mitochondrial pyruvate metabolism

British Journal of Pharmacology, EarlyView.
Background and Purpose Lobeglitazone is a thiazolidinedione and PPARγ agonist that improves metabolic parameters and hepatic steatosis, but its mechanisms are not fully understood. This study investigated the effects of lobeglitazone on hepatic transcriptomic and metabolic profiles in a rat model of obesity and Type 2 diabetes mellitus.
Hyekyung Yang, Su Young Son, Youngmi Song, Hyewon Choi, In‐Gu Do, Choong Hwan Lee, Cheol‐Young Park   +6 more
wiley   +1 more source